IBS Medication Guide: Prescription & OTC Options

Medical Disclaimer

This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your diet or treatment plan.

Key Takeaways

Peppermint oil capsules are the best-evidenced antispasmodic for IBS with a number needed to treat (NNT) of 4
Low-dose tricyclic antidepressants (e.g., amitriptyline 10-30 mg) act as neuromodulators for IBS pain — not as antidepressants
IBS-D and IBS-C require different medications — using the wrong one can worsen symptoms
Rifaximin is the only antibiotic approved for IBS-D and works primarily by reducing bloating and bacterial overgrowth
Medication works best when combined with dietary modification, stress management, and regular monitoring

Overview of Pharmacological Approaches to IBS

Medication for irritable bowel syndrome targets specific mechanisms within the gut-brain axis rather than the condition as a whole. Because IBS involves visceral hypersensitivity, altered motility, changes in intestinal secretion, low-grade immune activation, and dysregulated central processing, different drugs address different pieces of this puzzle. No single medication resolves all aspects of IBS, which is why pharmacotherapy is most effective as part of a broader management plan that includes dietary and psychological interventions.

The 2021 American College of Gastroenterology (ACG) guideline and the 2023 British Society of Gastroenterology (BSG) guideline both recommend a stepwise approach: lifestyle and dietary modifications first, antispasmodics for pain, then escalation to neuromodulators or subtype-specific agents as needed. According to Dr. Eswaran, "I think of medication as one tool in the toolbox — not the toolbox itself. The patients who do best are those who use medication to create a window of symptom relief that makes it easier to implement diet changes and stress management."

Before starting any IBS medication, it is important to have an accurate IBS subtype classification and to have excluded mimicking conditions such as coeliac disease, inflammatory bowel disease, and thyroid dysfunction. Medication choice should always be discussed with a healthcare provider who understands the full clinical picture.

Antispasmodics and Peppermint Oil

Antispasmodics reduce the intensity and frequency of intestinal smooth-muscle contractions, providing relief from cramping abdominal pain. Enteric-coated peppermint oil capsules are the most extensively studied antispasmodic for IBS. A 2019 systematic review and meta-analysis by Alammar and colleagues, published in BMC Complementary Medicine and Therapies, found that peppermint oil significantly improved global IBS symptoms and abdominal pain compared to placebo, with a number needed to treat (NNT) of approximately 4. The active component, L-menthol, acts as a calcium channel antagonist in intestinal smooth muscle, reducing contractile force.

Standard dosing for enteric-coated peppermint oil is 182–200 mg taken 30–60 minutes before meals, typically three times daily. The enteric coating is essential — without it, menthol is released in the stomach, which can cause heartburn and oesophageal reflux. Other antispasmodics commonly prescribed include hyoscine butylbromide (Buscopan), mebeverine, otilonium bromide, and pinaverium bromide. These agents have variable evidence quality; the ACG guideline conditionally recommends antispasmodics as a class but highlights peppermint oil as having the strongest individual data.

Antispasmodics are generally used on an as-needed basis for pain episodes rather than as daily scheduled therapy, though some patients benefit from regular dosing when symptoms are persistent. Side effects are typically mild — peppermint oil may cause heartburn or a minty aftertaste, while anticholinergic antispasmodics like hyoscine can cause dry mouth and constipation. Patients with IBS-C should be cautious with anticholinergic agents as they may worsen constipation.

Neuromodulators: Tricyclic Antidepressants and SSRIs

Gut-brain neuromodulators represent a paradigm shift in IBS treatment — they target the central and peripheral nervous system pathways that amplify gut symptoms rather than acting directly on the intestine. Low-dose tricyclic antidepressants (TCAs), particularly amitriptyline and nortriptyline, are the most well-studied neuromodulators for IBS. The ATLANTIS trial, a large randomised controlled trial published in The Lancet in 2023, demonstrated that low-dose amitriptyline (titrated from 10 mg to 30 mg at bedtime) significantly reduced IBS symptom severity scores compared to placebo over 6 months in a primary care setting.

TCAs work through multiple mechanisms at low doses: they modulate descending pain inhibitory pathways, slow intestinal transit (which is beneficial for IBS-D but may worsen IBS-C), reduce visceral hypersensitivity, and improve sleep quality. The doses used for IBS (10–50 mg) are far below the 150–300 mg range used for depression, and patients should be counselled that this prescription is not for a mental health condition. Common side effects include dry mouth, morning drowsiness, and constipation — effects that diminish over the first few weeks of use.

Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, citalopram, and paroxetine have a weaker evidence base for IBS than TCAs, but may be preferred in certain situations. SSRIs tend to accelerate gut transit, making them more suitable for IBS-C patients or those with comorbid anxiety or depression. According to Dr. Eswaran, "I typically start with a TCA for IBS-D patients and consider an SSRI for IBS-C patients or when a comorbid mood disorder would also benefit from treatment. The key is starting low and titrating slowly."

IBS-D Medications: Rifaximin, Eluxadoline, and Bile Acid Sequestrants

Rifaximin (Xifaxan) is a non-absorbable antibiotic that gained FDA approval for IBS-D based on two large phase III trials (TARGET 1 and TARGET 2). It is particularly effective for bloating-predominant IBS-D and works by modulating the intestinal microbiota, reducing bacterial fermentation and gas production, and potentially addressing small intestinal bacterial overgrowth (SIBO) that co-occurs in a subset of IBS-D patients. The standard regimen is 550 mg three times daily for 14 days, and the ACG guideline notes that retreatment is appropriate for symptom recurrence.

Eluxadoline (Viberzi) is a locally acting mixed mu-opioid receptor agonist and delta-opioid receptor antagonist. It reduces diarrhoea and abdominal pain by modulating opioid signalling in the enteric nervous system without causing the systemic effects of traditional opioids. However, eluxadoline carries an important safety consideration: it is contraindicated in patients who have had a cholecystectomy (gallbladder removal), as post-marketing reports identified a risk of sphincter of Oddi spasm leading to pancreatitis in this population.

Bile acid sequestrants, including cholestyramine, colesevelam, and colestipol, target the estimated 25–30% of IBS-D patients who have underlying bile acid malabsorption (BAM). When excess bile acids enter the colon, they stimulate fluid secretion and accelerate motility, producing watery diarrhoea. A SeHCAT test or a therapeutic trial of a bile acid sequestrant can help identify these patients. Research from the University of Michigan shows that correctly identifying and treating BAM in IBS-D patients produces dramatic improvement in a subgroup that otherwise responds poorly to standard IBS therapies.

IBS-C Medications: Linaclotide, Lubiprostone, and Plecanatide

Linaclotide (Linzess/Constella) is a guanylate cyclase-C (GC-C) receptor agonist that works on the luminal surface of intestinal epithelial cells. It increases intracellular cyclic GMP (cGMP), which stimulates chloride and bicarbonate secretion into the intestinal lumen, drawing water and accelerating transit. Crucially, cGMP also diffuses to submucosal afferent nerve endings and reduces their excitability, providing a direct analgesic effect on visceral pain — a benefit that sets linaclotide apart from simple laxatives. Clinical trials showed that linaclotide significantly improved both spontaneous bowel movements and abdominal pain compared to placebo.

Lubiprostone (Amitiza) is a chloride channel activator (specifically CIC-2 channels) that increases intestinal fluid secretion without directly affecting motility. It is taken as a 8-microgram capsule twice daily for IBS-C. Side effects include nausea (reported in up to 8% of patients), which can be minimised by taking the capsule with food. Plecanatide (Trulance) is another GC-C agonist that works similarly to linaclotide but is designed to mimic the endogenous peptide uroguanylin, potentially resulting in a more physiological pattern of activation. Both agents are well tolerated, with diarrhoea as the most common side effect — a paradoxical but expected consequence of increasing intestinal fluid output.

Prucalopride (Motegrity) is a selective serotonin 5-HT4 receptor agonist that stimulates colonic high-amplitude propagating contractions. Originally approved for chronic idiopathic constipation, it is increasingly used off-label for IBS-C when secretagogues are insufficient. According to Dr. Eswaran, "For IBS-C patients who need both pain relief and improved motility, linaclotide is usually my first-line prescription. If the primary issue is infrequent motility with less pain involvement, prucalopride can be an excellent alternative."

Combining Medication with Other Treatments

Medication rarely works optimally in isolation. The 2021 ACG guideline explicitly recommends integrating pharmacotherapy with dietary modification and, where appropriate, psychological therapy. In practice, this might look like starting a low-FODMAP diet and peppermint oil simultaneously, then adding a neuromodulator if pain persists after 4–6 weeks, and layering in gut-directed hypnotherapy for long-term central desensitisation. Each intervention addresses a different mechanism, and the combined effect is often greater than the sum of individual parts.

When combining medications, clinicians must consider drug interactions and overlapping side effects. For example, combining a tricyclic antidepressant with hyoscine butylbromide increases anticholinergic burden, potentially causing constipation, urinary retention, and cognitive effects — particularly in older adults. Similarly, using an SSRI alongside a TCA requires caution due to serotonin-related interactions. Always disclose all medications, including over-the-counter products and supplements, to your prescribing clinician.

Self-management tools play an important role in medication optimisation. Tracking symptoms in relation to medication timing, dosing, and dietary habits helps both patients and clinicians assess whether a medication is working, needs dose adjustment, or should be replaced. The goal is not to be on medication indefinitely in every case — some patients use pharmacotherapy to stabilise symptoms and then gradually taper once dietary and psychological interventions have taken full effect.

Sources

1. Lacy BE, Pimentel M, Brenner DM et al.. ACG Clinical Guideline: Management of Irritable Bowel Syndrome (2021).
2. Ford AC, Wright-Hughes A, Alderson SL et al.. Low-dose amitriptyline for irritable bowel syndrome (ATLANTIS): a randomised, double-blind, placebo-controlled trial (2023).
3. Alammar N, Wang L, Saberi B et al.. Efficacy of peppermint oil in irritable bowel syndrome: a systematic review and meta-analysis (2019).
4. Pimentel M, Lembo A, Chey WD et al.. Rifaximin therapy for patients with irritable bowel syndrome without constipation (TARGET) (2011).
5. Vasant DH, Paine PA, Black CJ et al.. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome (2021).

Frequently Asked Questions

What is the best medication for IBS?

There is no single best medication for IBS because the condition involves multiple mechanisms and varies by subtype. For pain and cramping, peppermint oil has the strongest evidence among antispasmodics. For IBS-D, rifaximin or low-dose amitriptyline may be effective. For IBS-C, linaclotide addresses both pain and constipation. Your doctor will recommend based on your specific subtype and symptoms.

Can I buy IBS medication over the counter?

Several IBS medications are available without a prescription, including peppermint oil capsules, loperamide (for IBS-D diarrhoea), psyllium fibre supplements, and antispasmodics like hyoscine butylbromide (in some countries). However, neuromodulators, secretagogues, rifaximin, and eluxadoline all require a prescription. Over-the-counter options can be a helpful starting point, but persistent symptoms warrant a medical consultation.

Are antidepressants for IBS safe if I am not depressed?

Yes. When prescribed for IBS, antidepressants are used at low doses that target gut-brain nerve signalling rather than brain chemistry related to mood. At these doses (typically 10-30 mg for amitriptyline), the medication acts as a neuromodulator for visceral pain. Side effects like dry mouth and drowsiness usually diminish after the first few weeks. Discuss any concerns with your prescribing doctor.

How long should I try an IBS medication before deciding it does not work?

It depends on the medication class. Antispasmodics like peppermint oil should show effects within a few days to a week. Neuromodulators (TCAs, SSRIs) typically require 4-6 weeks at a therapeutic dose to reach full effect. Secretagogues like linaclotide usually show improvement within 1-2 weeks for constipation, though pain reduction may take 4-6 weeks. Rifaximin is taken for a 14-day course, with benefits sometimes appearing only after the course is complete.

Can I take IBS medication while following the low-FODMAP diet?

Yes, and many gastroenterologists recommend this combination. The medication and the diet target different mechanisms — for example, peppermint oil reduces muscle spasm while the low-FODMAP diet reduces fermentation and osmotic load. Combining approaches often produces better results than either alone. Just be mindful that some medications come in capsules or syrups that contain FODMAPs (e.g., sorbitol, lactose), so check inactive ingredients.

Will I need to take IBS medication forever?

Not necessarily. Some patients use medication as a bridge while establishing dietary and psychological management strategies, then gradually taper. Others with more severe symptoms benefit from long-term pharmacotherapy. Neuromodulators are often trialled for 6-12 months and then tapered to see if benefits persist. The decision to continue, taper, or switch should be made collaboratively with your healthcare provider based on symptom response.

Is rifaximin an antibiotic — will it cause antibiotic resistance?

Rifaximin is a non-absorbable antibiotic, meaning it acts locally in the gut with minimal systemic absorption. Studies have not shown significant antibiotic resistance development with rifaximin use in IBS. Its mechanism in IBS appears to involve modulating the gut microbiota and reducing bacterial fermentation rather than eradicating specific pathogens, which may explain the lower resistance risk compared to systemic antibiotics.